7Baggers

Voyager Therapeutics, Inc
(NASDAQ:VYGR) 

VYGR stock logo

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's ...

Founded: 2013
Full Time Employees: 185
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
                                               
      collaboration revenue
    		2,593,000 15,336,000 13,365,000 5,200,000 6,473,000 6,278,000 24,629,000 29,578,000 19,516,000 90,061,000 4,614,000 4,853,000 150,480,000 -1,550,000 41,086,000 712,000 658,000 28,073,000 1,482,000 1,357,000 6,501,000 6,537,000 117,843,000 28,681,000 18,067,000 32,674,000 20,433,000 46,087,000 5,197,000 2,008,000 2,094,000 2,575,000 942,000 6,345,000 1,148,000 1,177,000 1,464,000 2,362,000 3,308,000 3,720,000 4,830,000 4,937,000 4,937,000 
      operating expenses:
    		                                           
      research and development
    		24,602,000 35,952,000 35,866,000 31,330,000 31,526,000 35,583,000 30,241,000 34,452,000 27,092,000 25,756,000 25,863,000 21,985,000 18,568,000 14,551,000 19,337,000 12,527,000 14,349,000 14,020,000 17,914,000 19,505,000 22,346,000 21,996,000 25,039,000 29,423,000 32,294,000 36,551,000 29,777,000 28,576,000 24,831,000 16,914,000 16,632,000 16,507,000 14,853,000 13,327,000 19,561,000 15,300,000 14,072,000 12,723,000 10,309,000 10,484,000 8,732,000 9,220,000 6,481,000 
      general and administrative
    		8,261,000 9,316,000 8,093,000 10,495,000 9,640,000 8,994,000 8,168,000 10,151,000 8,607,000 10,242,000 8,258,000 8,294,000 9,028,000 8,462,000 7,307,000 7,552,000 7,659,000 8,351,000 8,714,000 10,437,000 9,744,000 8,270,000 8,277,000 8,239,000 10,206,000 9,891,000 8,463,000 8,322,000 9,659,000 8,255,000 6,609,000 11,762,000 7,182,000 5,366,000 4,942,000 4,516,000 4,914,000 3,481,000 3,370,000 2,854,000 3,565,000 3,157,000 2,475,000 
      total operating expenses
    		32,863,000 45,268,000 43,959,000 41,825,000 41,166,000 44,577,000 38,409,000 44,603,000 35,699,000 35,998,000 34,121,000 30,279,000 27,596,000 23,013,000 26,644,000 20,079,000 22,008,000 22,371,000 26,628,000 29,942,000 32,090,000 30,266,000 33,316,000 37,662,000 42,500,000 46,442,000 38,240,000 36,898,000 34,490,000 25,169,000 23,241,000 28,269,000 22,035,000 18,693,000 24,503,000 19,816,000 18,986,000 16,204,000 13,679,000 13,338,000 12,297,000 12,377,000 8,956,000 
      operating income
    		-30,270,000 -29,932,000 -30,594,000 -36,625,000 -34,693,000 -38,299,000 -13,780,000 -15,025,000 -16,183,000 54,063,000 -29,507,000 -25,426,000 122,884,000 -24,563,000 14,442,000 -19,367,000 -21,350,000 5,702,000 -25,146,000 -28,585,000 -25,589,000 -23,729,000 84,527,000 -8,981,000 -24,433,000 -13,768,000 -17,807,000 9,189,000 -29,293,000 -23,161,000 -21,147,000 -25,694,000 -21,093,000 -12,348,000 -23,355,000 -18,639,000 -17,522,000 -13,842,000 -10,371,000 -9,618,000 -7,467,000 -7,440,000 -4,019,000 
      yoy
    		-12.75% -21.85% 122.02% 143.76% 114.38% -170.84% -53.30% -40.91% -113.17% -320.10% -304.31% 31.29% -675.57% -530.78% -157.43% -32.25% -16.57% -124.03% -129.75% 218.28% 4.73% 72.35% -574.68% -197.74% -16.59% -40.56% -15.79% -135.76% 38.88% 87.57% -9.45% 37.85% 20.38% -10.79% 125.20% 93.79% 134.66% 86.05% 158.05%     
      qoq
    		1.13% -2.16% -16.47% 5.57% -9.42% 177.93% -8.29% -7.16% -129.93% -283.22% 16.05% -120.69% -600.28% -270.08% -174.57% -9.29% -474.43% -122.68% -12.03% 11.71% 7.84% -128.07% -1041.18% -63.24% 77.46% -22.68% -293.79% -131.37% 26.48% 9.52% -17.70% 21.81% 70.82% -47.13% 25.30% 6.37% 26.59% 33.47% 7.83% 28.81% 0.36% 85.12%  
      other income, net:
    		                                           
      interest income
    		1,912,000 2,111,000 2,385,000 2,831,000 3,291,000 3,994,000 4,579,000 4,888,000 4,867,000 3,154,000 3,429,000 3,274,000 1,864,000 976,000 545,000 219,000 31,000 -643,000 121,000 48,000 19,000 81,000 254,000 346,000 978,000 1,392,000 1,823,000 2,097,000 1,145,000 911,000 942,000 870,000 588,000 428,000 291,000 255,000 253,000 -1,093,000 1,171,000 433,000 465,000 157,000 102,000 
      other income
    		435,000 404,000 400,000 427,000 418,000 402,000 200,000 20,000      -23,000 2,637,000 61,000  650,000 -112,000 -1,583,000 3,921,000 7,722,000 830,000 -46,000 -808,000 -198,000 978,000 -133,000 978,000   -717,000 399,000   -297,000 395,000       
      total other income
    		2,347,000 2,515,000 2,785,000 3,258,000 3,709,000 4,396,000 4,779,000 4,908,000 4,867,000 3,154,000 3,429,000 3,277,000 1,864,000 953,000 3,182,000 280,000 31,000 7,000 9,000 -1,535,000 3,940,000 7,803,000 1,084,000 300,000 170,000 1,194,000 2,801,000 1,964,000 2,123,000 630,000 858,000 153,000 987,000 550,000 9,000 -42,000 648,000 -476,000 1,072,000 283,000 279,000   
      income before income taxes
    		-27,923,000 -27,417,000 -27,809,000 -33,367,000 -30,984,000 -33,903,000 -9,001,000 -10,117,000 -11,316,000 57,217,000 -26,078,000 -22,149,000 124,748,000             -12,574,000 -15,006,000 11,153,000 -27,170,000 -22,531,000 -20,289,000 -25,541,000 -20,106,000 -11,798,000 -23,346,000 -18,681,000 -16,874,000 -14,318,000 -9,299,000     
      income tax provision
    		14,000 9,000 83,000 15,000 37,000 584,000 43,000 24,000 14,000 822,000 -177,000 59,000 704,000                       -195,000 226,000       
      net income
    		-27,937,000 -27,426,000 -27,892,000 -33,382,000 -31,021,000 -34,487,000 -9,044,000 -10,141,000 -11,330,000 56,395,000 -25,901,000 -22,208,000 124,044,000 -23,626,000 17,624,000 -19,087,000 -21,319,000 5,709,000 -25,137,000 -30,120,000 -21,649,000 -15,926,000 85,611,000 -8,681,000 -24,263,000 -12,574,000 -15,006,000 11,153,000 -27,170,000 -22,531,000 -20,289,000 -25,541,000 -19,926,000 -11,829,000 -23,346,000 -18,876,000 -16,648,000 -14,673,000 -8,996,000 -9,335,000 -7,188,000 -7,283,000 -3,917,000 
      yoy
    		-9.94% -20.47% 208.40% 229.18% 173.80% -161.15% -65.08% -54.34% -109.13% -338.70% -246.96% 16.35% -681.85% -513.84% -170.11% -36.63% -1.52% -135.85% -129.36% 246.96% -10.77% 26.66% -670.51% -177.84% -10.70% -44.19% -26.04% -143.67% 36.35% 90.47% -13.09% 35.31% 19.69% -19.38% 159.52% 102.21% 131.61% 101.47% 129.67%     
      qoq
    		1.86% -1.67% -16.45% 7.61% -10.05% 281.32% -10.82% -10.49% -120.09% -317.73% 16.63% -117.90% -625.03% -234.06% -192.34% -10.47% -473.43% -122.71% -16.54% 39.13% 35.93% -118.60% -1086.19% -64.22% 92.96% -16.21% -234.55% -141.05% 20.59% 11.05% -20.56% 28.18% 68.45% -49.33% 23.68% 13.38% 13.46% 63.11% -3.63% 29.87% -1.30% 85.93%  
      other comprehensive income:
    		                                           
      net unrealized gain on available-for-sale securities
    		-295,000 103,500 228,000 -22,000 208,000 3,750 489,000 -16,000 -458,000 -7,250 -115,000 -1,000 87,000 -49,750 27,000 -141,000 -85,000 1,500 -2,000 -3,000 11,000 11,000 -205,000 -276,000 525,000 29,500 -116,000 176,000 58,000               
      total other comprehensive income
    		-295,000 25,000 228,000 -22,000  -374,000 489,000 -16,000 -458,000 200,000 -115,000 -1,000 87,000 -49,750 27,000 -141,000 -85,000 -10,000 -2,000 -3,000 11,000 -74,000 -205,000 -276,000 525,000 -89,000 -116,000 176,000 58,000 -74,000 -49,000 37,000 120,000 168,000 -485,000 -295,000 377,000 220,250 570,000     
      comprehensive loss
    		-28,232,000 -22,970,250 -27,664,000 -33,404,000 -30,813,000           -19,228,000 -21,404,000   -30,123,000 -21,638,000    -23,738,000 -12,663,000 -15,122,000  -27,112,000 -22,605,000 -20,338,000 -25,504,000 -19,806,000 -11,661,000 -23,831,000 -19,171,000 -16,271,000 -15,355,000 -8,426,000 -9,305,000 -6,907,000 -7,572,000 -3,859,000 
      net income per share
    		-0.47 -0.47 -0.47 -0.57 -0.53 -0.6 -0.16 -0.18 -0.2 1.23 -0.59 -0.51 3.05 -0.62 0.46 -0.5 -0.56 0.15 -0.67 -0.8 -0.58 -0.43 2.3 -0.23 -0.66 -0.34 -0.41 0.3 -0.81 -0.69 -0.63 -0.8 -0.63 -0.37 -0.89 -0.73 -0.65 -0.58 -0.35 -0.37 -0.29 16.22 -5.25 
      weighted-average common shares outstanding, basic and diluted
    		59,496,329  58,803,015             38,298,426 38,049,430   37,581,381 37,501,065    36,963,255 35,898,266 36,742,993  33,353,061 32,065,781 32,191,475 31,976,922 31,759,870 26,803,711 26,164,527 25,946,333 25,791,591 25,302,414 25,374,381 25,228,405 25,076,769 4,191,210 1,317,150 
      weighted-average common shares outstanding, basic
    		 58,691,136  58,666,460 58,349,769 57,667,543 57,851,110 57,721,934 57,117,046 43,020,747 43,864,838 43,520,137 40,632,087 38,356,810 38,507,542   37,668,947 37,780,547   37,132,447 37,242,504 37,029,524    36,610,918                
      weighted-average common shares outstanding, diluted
    		 58,691,136  58,666,460 58,349,769 57,667,543 57,851,110 57,721,934 57,117,046 44,569,334 43,864,838 43,520,137 42,161,326 38,356,810 39,570,394   37,668,947 37,780,547   37,348,514 37,672,328 37,029,524    37,941,257                
      other comprehensive gain:
    		                                           
      total other comprehensive gain
    		    208,000                                   30,000 281,000 9,500 58,000 
      comprehensive income
    		     -34,861,000 -8,555,000 -10,157,000 -11,788,000 56,595,000 -26,016,000 -22,209,000 124,131,000 -23,508,000 17,651,000   5,699,000 -25,139,000   -16,000,000 85,406,000 -8,957,000    11,329,000                
      other income:
    		           3,000                                
      other comprehensive income
    		                                           
      other income :
    		                                           
      income tax benefit
    		                             45,000   180,000 7,750    75,750 303,000     
      cumulative effect adjustment resulting from asu no. 2016-01
    		                                           
      other expense
    		                             -100,500 -84,000   -46,000 -282,000   -108,750 -99,000 -150,000 -186,000   
      unrealized gain on available-for-sale- securities, net of income tax benefit of 53 for the three months ended september 30, 2017
    		                             27,000 -49,000             
      unrealized gain on available-for-sale- securities, net of income tax provision of (191) and 53 for the three and six months ended june 30, 2017, respectively
    		                               37,000            
      net unrealized gain on available-for-sale-securities, net of tax expense of 244 for the three months ended march, 31 2017
    		                                120,000    377,000       
      unrealized gain on available-for-sale-securities, net of income tax provision of (53) for the three months ended september 30, 2017, and 570 for the three and nine months ended september 30, 2016
    		                                 -100,750 -485,000         
      unrealized gain on available-for-sale- securities, net of income tax provision of (191) and 53 for the three and six months ended june 30, 2017, respectively
    		                                   -295,000        
      reconciliation of net loss to net loss attributable to common stockholders:
    		                                           
      net loss attributable to common stockholders
    		                                    -16,648,000 -14,673,000 -8,996,000 -9,335,000 -7,188,000 -8,817,000 -6,914,000 
      net unrealized gain on available-for-sale-securities, net of tax expense of 570 for the three and nine months ended september 30, 2016
    		                                     220,250 570,000     
      accretion of redeemable convertible preferred stock to redemption value
    		                                         -1,328,000 -2,594,000 
      accrued dividends on series a preferred stock
    		                                           
      other comprehensive loss
    		                                           
      net unrealized gain on available-for-sale-securities
    		                                       30,000 281,000 9,500 58,000 
      other financing expense
    		                                         -2,437,500  
      total other expense
    		                                         157,000 102,000 
      other comprehensive gain
    		                                           
      accrued dividends on series a redeemable convertible preferred stock
    		                                         -259,750 -403,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
                                                 
        assets
      		                                           
        current assets:
      		                                           
        cash and cash equivalents
      		43,314,000 65,300,000 45,125,000 43,940,000 74,755,000 71,367,000 112,525,000 76,127,000 143,078,000 68,802,000 65,269,000 244,293,000 268,321,000 98,959,000 96,860,000 78,329,000 131,873,000 117,433,000 111,475,000 117,844,000 117,799,000 104,440,000 147,447,000 144,321,000 165,227,000 86,042,000 82,640,000 79,885,000 113,261,000 46,859,000 42,142,000 59,614,000 140,371,000 31,530,000 48,201,000 66,300,000 43,604,000 36,641,000 63,507,000 67,032,000 33,895,000 31,309,000 66,533,000 
        marketable securities
      		98,165,000 131,147,000 163,805,000 171,653,000 161,264,000 195,317,000    162,073,000   4,993,000 19,889,000   34,960,000 15,106,000  25,137,000 43,707,000                      41,138,000 
        accounts receivable
      		1,494,000 1,761,000 3,186,000 1,674,000 1,623,000 1,504,000 15,954,000 1,702,000 837,000 80,150,000   25,000,000  10,000,000                             
        related party collaboration receivable
      		151,000 151,000 851,000 851,000 487,000 676,000 3,714,000 1,549,000 2,620,000 3,341,000 3,253,000 3,350,000 328,000 257,000 225,000 151,000 206,000 732,000 1,165,000 1,758,000 4,253,000 8,012,000 12,689,000 12,686,000 16,283,000 18,496,000                  
        prepaid expenses and other current assets
      		3,857,000 4,328,000 6,618,000 9,771,000 7,077,000 7,945,000 8,415,000 7,298,000 6,112,000 5,318,000 5,736,000 6,080,000 3,983,000 5,394,000 5,079,000 3,421,000 3,612,000 3,427,000 3,540,000 3,910,000 10,078,000 8,619,000 3,606,000 4,301,000 5,262,000 4,630,000 6,164,000 3,250,000 6,668,000 6,675,000 2,865,000 4,122,000 2,433,000 2,738,000 2,604,000 3,403,000 3,410,000 4,368,000 1,868,000 1,484,000 1,706,000 1,557,000 942,000 
        total current assets
      		146,981,000 202,687,000 219,585,000 227,889,000 245,206,000 276,809,000 373,443,000 381,570,000 409,137,000 319,684,000 261,925,000 282,176,000 302,625,000 124,499,000 146,942,000 151,628,000 170,651,000 136,698,000 126,204,000 148,649,000 175,837,000 197,769,000 216,313,000 246,657,000 272,476,000 304,659,000 327,597,000 340,775,000 365,167,000 162,481,000 182,466,000 200,245,000 220,631,000 171,790,000 128,191,000 144,726,000 161,080,000 178,786,000 193,021,000 205,477,000 205,698,000 195,894,000 108,613,000 
        property and equipment
      		12,218,000 13,136,000 13,291,000 13,919,000 13,929,000 14,314,000 15,201,000 16,267,000 17,381,000 16,494,000 17,109,000 17,239,000 17,138,000 17,857,000 18,082,000 19,071,000 19,374,000 21,920,000 22,992,000 23,689,000 24,520,000 25,435,000 23,212,000 20,205,000 18,586,000 17,986,000 15,292,000 14,493,000 13,146,000 12,771,000 12,527,000 12,244,000 11,458,000 10,283,000 10,558,000 10,674,000 10,134,000 7,893,000 4,253,000 3,603,000 3,558,000 3,234,000 3,277,000 
        restricted cash
      		2,736,000 2,736,000 5,614,000 2,874,000 2,874,000 2,874,000                                      
        marketable securities, non-current
      		30,181,000    59,103,000 65,704,000   980,000              2,184,000 1,422,000 1,432,000 1,920,000 2,024,000 1,280,000 1,280,000 628,000 800,000 860,000 1,320,000 1,100,000 960,000 1,480,000 2,000,000 1,360,000 2,416,000     
        operating lease, right-of-use assets
      		27,209,000  29,740,000 30,973,000 32,128,000 33,349,000 34,523,000 35,514,000 39,204,000 13,510,000 14,026,000 14,528,000 15,016,000 15,485,000   32,378,000 33,458,000   35,113,000 36,064,000                      
        total assets
      		219,325,000 252,281,000 288,311,000 322,101,000 353,240,000 393,050,000 426,041,000 436,225,000 469,592,000 351,281,000 294,653,000 315,536,000 336,294,000 159,356,000 182,480,000 188,605,000 224,182,000 193,855,000 184,774,000 208,727,000 237,717,000 261,584,000 269,757,000 297,455,000 322,610,000 354,760,000 376,220,000 388,592,000 411,349,000 177,029,000 197,064,000 214,663,000 235,026,000 184,477,000 140,915,000 158,414,000 175,090,000 189,566,000 201,984,000 209,815,000 219,980,000 229,457,000 166,435,000 
        liabilities and stockholders’ equity
      		                                           
        current liabilities:
      		                                           
        accounts payable
      		2,723,000 5,013,000 2,116,000 1,804,000 2,634,000 3,996,000 3,160,000 2,605,000 7,579,000 1,604,000 3,270,000 1,659,000 3,698,000 2,566,000 1,337,000 1,218,000 1,200,000 574,000 592,000 790,000 3,177,000 634,000 3,386,000 2,045,000 4,815,000 4,070,000 4,026,000 2,230,000 2,261,000 1,038,000 1,422,000 1,558,000 1,372,000 1,020,000 911,000 307,000 557,000 550,000 787,000 454,000 1,697,000 612,000 541,000 
        accrued expenses
      		6,972,000 12,098,000 14,953,000 12,025,000 9,053,000 14,171,000 11,442,000 10,273,000 7,595,000 16,823,000 11,051,000 9,060,000 7,639,000 7,816,000 12,529,000 7,185,000 7,735,000 10,950,000 11,324,000 10,959,000 10,535,000 14,205,000 21,665,000 18,154,000 17,493,000 21,516,000 16,588,000 11,782,000 9,276,000 9,788,000 8,355,000 7,697,000 9,351,000 11,497,000 10,493,000 7,314,000 5,593,000 6,488,000 6,304,000 5,049,000 2,661,000 3,430,000 2,942,000 
        operating lease liabilities
      		7,363,000 7,840,000 7,848,000 7,637,000 7,430,000 7,227,000                                      
        deferred revenue
      		395,000 1,590,000 10,578,000 20,517,000 21,095,000                                       
        total current liabilities
      		17,453,000 26,541,000 35,495,000 41,983,000 40,212,000 49,788,000 44,210,000 40,130,000 72,553,000 64,508,000 61,688,000 45,398,000 19,939,000 72,591,000 73,242,000 97,932,000 101,677,000 50,981,000 26,701,000 24,688,000 24,751,000 26,766,000 42,052,000 67,531,000 72,537,000 76,012,000 80,172,000 69,146,000 58,776,000 31,673,000 30,027,000 29,095,000 30,940,000 15,897,000 20,941,000 11,836,000 11,064,000 13,802,000 19,387,000 19,760,000 23,077,000 23,931,000 23,366,000 
        operating lease liabilities, net of current portion
      		27,203,000 28,659,000 30,520,000 32,567,000 34,566,000 36,499,000                                      
        other non-current liabilities
      		1,000,000 1,000,000 1,000,000 1,000,000 1,000,000 1,000,000 39,368,000 41,205,000 42,996,000 18,094,000 18,919,000 19,729,000 20,522,000 21,295,000 22,024,000 22,741,000 38,125,000 39,609,000 41,012,000 41,847,000 43,144,000 44,410,000 29,260,000 30,184,000 31,089,000 31,976,000 32,799,000 33,606,000 34,396,000 1,001,000 1,003,000 1,006,000 1,008,000 1,012,000 1,015,000 1,019,000 1,023,000 25,000 29,000 34,000 40,000 44,000 52,000 
        total liabilities
      		45,656,000 56,200,000 68,486,000 78,157,000 80,538,000 93,290,000 95,731,000 100,808,000 128,706,000 114,961,000 118,433,000 116,510,000 119,333,000 100,336,000 102,657,000 128,553,000 148,251,000 98,800,000 97,352,000 98,191,000 101,509,000 107,264,000 103,521,000 220,571,000 242,853,000 255,248,000 268,064,000 270,188,000 310,655,000 130,583,000 131,476,000 132,691,000 136,733,000 50,426,000 55,709,000 53,123,000 52,393,000 53,644,000 52,860,000 54,111,000 56,383,000 60,383,000 64,716,000 
        commitments, contingencies, and other liabilities
      		                                           
        stockholders’ equity:
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at march 31, 2026 and december 31, 2025; no shares issued and outstanding at march 31, 2026 and december 31, 2025
      		                                           
        common stock
      		60,000 59,000 56,000 56,000 55,000 55,000 55,000 54,000 54,000 44,000 44,000 44,000 43,000 38,000 38,000 38,000 38,000 38,000 38,000 38,000 38,000 37,000 37,000 37,000 37,000 37,000 37,000 37,000 37,000 32,000 32,000 32,000 32,000 32,000 26,000 26,000 26,000 26,000 25,000 25,000 25,000 25,000 1,000 
        additional paid-in capital
      		647,714,000 641,895,000 638,241,000 634,696,000 630,051,000 626,296,000 621,985,000 618,538,000 613,850,000 497,506,000 494,001,000 490,791,000 486,518,000 452,713,000 450,008,000 447,888,000 444,539,000 442,259,000 440,325,000 438,300,000 433,849,000 430,324,000 426,240,000 422,294,000 416,210,000 412,227,000 408,208,000 403,334,000 396,953,000 315,598,000 312,250,000 308,296,000 299,112,000 295,019,000 234,519,000 230,773,000 229,009,000 225,963,000 223,811,000 221,964,000 220,552,000 219,122,000  
        accumulated other comprehensive income
      		-263,000 32,000 7,000                     145,000 421,000   101,000        30,000 325,000  630,000 60,000 30,000   
        accumulated deficit
      		-473,842,000 -445,905,000 -418,479,000 -390,587,000 -357,205,000 -326,184,000 -291,697,000 -282,653,000 -272,512,000 -261,182,000 -317,577,000 -291,676,000 -269,468,000 -393,512,000 -369,886,000 -387,510,000 -368,423,000 -347,104,000 -352,813,000 -327,676,000 -297,556,000 -275,907,000 -259,981,000 -345,592,000 -336,911,000 -312,648,000 -300,074,000 -285,068,000 -296,221,000 -269,051,000 -246,520,000 -226,231,000 -200,689,000 -160,713,000 -148,884,000 -125,538,000 -106,663,000 -90,015,000 -75,342,000 -66,345,000 -57,010,000 -49,822,000 -47,178,000 
        total stockholders’ equity
      		173,669,000 196,081,000 219,825,000 243,944,000 272,702,000 299,760,000 330,310,000 335,417,000 340,886,000 236,320,000 176,220,000 199,026,000 216,961,000 59,020,000 79,823,000 60,052,000 75,931,000 95,055,000 87,422,000 110,536,000 136,208,000 154,320,000 166,236,000 76,884,000 79,757,000 99,512,000 108,156,000 118,404,000 100,694,000 46,446,000 65,588,000 81,972,000 98,293,000 134,051,000 85,206,000 105,291,000 122,697,000 135,922,000 149,124,000 155,704,000 163,597,000 169,074,000  
        total liabilities and stockholders’ equity
      		219,325,000 252,281,000 288,311,000 322,101,000 353,240,000 393,050,000 426,041,000 436,225,000 469,592,000 351,281,000 294,653,000 315,536,000 336,294,000 159,356,000 182,480,000 188,605,000 224,182,000 193,855,000 184,774,000 208,727,000 237,717,000 261,584,000 269,757,000 297,455,000 322,610,000 354,760,000 376,220,000 388,592,000 411,349,000 177,029,000 197,064,000 214,663,000 235,026,000 184,477,000 140,915,000 158,414,000 175,090,000 189,566,000 201,984,000 209,815,000 219,980,000   
        operating lease right-of-use assets
      		 28,478,000                                          
        deferred revenue, net of current portion
      		  1,471,000 2,607,000 4,760,000                        217,483,000 92,199,000 94,804,000 97,308,000 99,506,000 28,180,000 28,368,000 34,838,000 35,248,000 34,818,000 31,456,000 32,927,000 31,914,000 35,393,000 40,205,000 
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2025 and 2024
      		                                           
        commitments and contingencies
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at september 30, 2025 and december 31, 2024; no shares issued and outstanding at september 30, 2025 and december 31, 2024
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at june 30, 2025 and december 31, 2024; no shares issued and outstanding at june 30, 2025 and december 31, 2024
      		                                           
        accumulated other comprehensive loss
      		   -221,000 -199,000 -407,000 -33,000 -522,000 -506,000 -48,000 -248,000 -133,000 -132,000 -219,000 -337,000 -364,000 -223,000 -138,000 -128,000 -126,000 -123,000 -134,000 -60,000   -104,000 -15,000  -75,000 -133,000 -174,000 -125,000 -162,000 -287,000 -455,000   -52,000    -251,000  
        preferred stock, 0.001 par value: 5,000,000 shares authorized at march 31, 2025 and december 31, 2024; no shares issued and outstanding at march 31, 2025 and december 31, 2024
      		                                           
        deferred revenue, current
      		     24,394,000 22,629,000 20,516,000 51,439,000 42,881,000 44,261,000 31,666,000 5,680,000 59,377,000 56,630,000 87,003,000 86,994,000 33,886,000 9,537,000 8,069,000 6,443,000 7,729,000 13,462,000 43,911,000 46,923,000 47,233,000 56,542,000 52,291,000                
        deferred revenue, non-current
      		     6,003,000 12,153,000 19,473,000 13,157,000 32,359,000 37,826,000 51,383,000 78,872,000 6,450,000 7,391,000 7,880,000 8,449,000 8,210,000 29,639,000 31,656,000 33,614,000 36,088,000 32,209,000 122,856,000 139,227,000 147,260,000 155,093,000 167,436,000                
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2024 and 2023
      		                                           
        marketable securities, current
      		      232,835,000 294,894,000 256,490,000  187,667,000 28,453,000   34,778,000 69,727,000   10,024,000   76,698,000 52,571,000 85,349,000 85,704,000 195,491,000 224,760,000 247,577,000 245,238,000 108,947,000 137,459,000 136,509,000 77,827,000 137,522,000 77,386,000 75,023,000 114,066,000 137,777,000 127,646,000     
        deposits and other non-current assets
      		      2,874,000 2,874,000 2,890,000 1,593,000 1,593,000 1,593,000 1,515,000 1,515,000 1,515,000 1,515,000 1,779,000 1,779,000 1,779,000 2,247,000 2,247,000 2,316,000 1,917,000 2,183,000 2,378,000 1,723,000 1,976,000 2,003,000 1,462,000 1,149,000 1,271,000 1,314,000 1,617,000 1,304,000 1,206,000 1,534,000 1,876,000 1,527,000 2,294,000 735,000 735,000 321,000 1,623,000 
        other current liabilities
      		      6,979,000 6,736,000 5,940,000 3,200,000 3,106,000 3,013,000 2,922,000 2,832,000 2,746,000 2,526,000 5,748,000 5,571,000 5,248,000 4,870,000 4,596,000 4,198,000 3,539,000 3,421,000 3,306,000 3,193,000 3,016,000 2,843,000 2,673,000               
        preferred stock, 0.001 par value: 5,000,000 shares authorized at september 30, 2024 and december 31, 2023; no shares issued and outstanding at september 30, 2024 and december 31, 2023
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at june 30, 2024 and december 31, 2023; no shares issued and outstanding at june 30, 2024 and december 31, 2023
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at march 31, 2024 and december 31, 2023; no shares issued and outstanding at march 31, 2024 and december 31, 2023
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2023 and 2022
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued and outstanding at september 30, 2023 and december 31, 2022
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued and outstanding at june 30, 2023 and december 31, 2022
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued and outstanding at march 31, 2023 and december 31, 2022
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2022 and 2021
      		                                           
        operating lease, right-of-use asset
      		              15,941,000 16,391,000   33,799,000 34,142,000   26,131,000 26,988,000 27,738,000 28,472,000 29,331,000 30,041,000 30,294,000               
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2022 and december 31, 2021; no shares issued and outstanding at september 30, 2022 and december 31, 2021
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2022 and december 31, 2021; no shares issued and outstanding at june 30, 2022 and december 31, 2021
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2022 and december 31, 2021; no shares issued and outstanding at march 31, 2022 and december 31, 2021
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2021 and 2020
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2021 and december 31, 2020; no shares issued and outstanding at september 30, 2021 and december 31, 2020
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2021 and december 31, 2020; no shares issued and outstanding at june 30, 2021 and december 31, 2020
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2021 and december 31, 2020; no shares issued and outstanding at march 31, 2021 and december 31, 2020
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2020 and 2019
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2020 and december 31, 2019; no shares issued and outstanding at september 30, 2020 and december 31, 2019
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2020 and december 31, 2019; no shares issued and outstanding at june 30, 2020 and december 31, 2019
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2020 and december 31, 2019; no shares issued and outstanding at march 31, 2020 and december 31, 2019
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2019 and 2018
      		                                           
        collaboration receivable
      		                          11,733,000 8,242,000                
        unbilled receivable
      		                          2,300,000 1,821,000                
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2019 and december 31, 2018; no shares issued and outstanding at september 30, 2019 and december 31, 2018
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2019 and december 31, 2018; no shares issued and outstanding at june 30, 2019 and december 31, 2018
      		                                           
        deferred revenue, current portion
      		                            44,566,000 20,847,000 20,250,000 19,840,000 20,217,000 3,380,000 9,537,000 4,215,000 4,914,000 6,764,000 12,296,000 14,257,000 18,719,000 19,589,000 19,589,000 
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2019 and december 31, 2018; no shares issued and outstanding at march 31, 2019 and december 31, 2018
      		                                           
        deferred rent
      		                             5,710,000 5,642,000 5,282,000 5,279,000 5,337,000 5,385,000 5,430,000 5,058,000       
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2018 and 2017
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2018 and december 31, 2017; no shares issued and outstanding at september 30, 2018 and december 31, 2017
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2018 and december 31, 2017; no shares issued and outstanding at june 30, 2018 and december 31, 2017
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2018 and december 31, 2017; no shares issued and outstanding at march 31, 2018 and december 31, 2017
      		                                           
        preferred stock, 0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at december 31, 2017 and 2016
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2017 and december 31, 2016; no shares issued and outstanding at september 30, 2017 and december 31, 2016
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2017 and december 31, 2016; no shares issued and outstanding at june 30, 2017 and december 31, 2016
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2017 and december 31, 2016; no shares issued and outstanding at march 31, 2017 and december 31, 2016
      		                                           
        deferred rent, current portion
      		                                         300,000 294,000 
        deferred rent, net of current portion
      		                                     4,999,000 1,988,000 1,390,000 1,352,000 1,015,000 1,093,000 
        preferred stock, 0.001 par value: 5,000,000 shares authorized; 0 shares issued and outstanding at december 31, 2016 and 2015
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at september 30, 2016 and december 31, 2015; no shares issued and outstanding at september 30, 2016 and december 31, 2015
      		                                           
        marketable investments, current
      		                                       136,961,000 170,097,000 163,028,000  
        marketable investments, non-current
      		                                        9,989,000 30,008,000  
        preferred stock 0.001 par value: 5,000,000 shares authorized at june 30, 2016 and december 31, 2015; no shares issued and outstanding at june 30, 2016 and december 31, 2015
      		                                           
        preferred stock 0.001 par value: 5,000,000 shares authorized at march 31, 2016 and december 31, 2015; no shares issued and outstanding at march 31, 2016 and december 31, 2015
      		                                           
        liabilities, redeemable convertible preferred stock and stockholders’ equity
      		                                           
        preferred stock tranche liability
      		                                           
        redeemable convertible preferred stock
      		                                          59,863,000 
        stockholders’ equity
      		                                           
        preferred stock 0.001 par value: 5,000,000 and 0 shares authorized at december 31, 2015 and 2014, respectively; 0 shares issued and outstanding at december 31, 2015 and 2014
      		                                           
        total liabilities, redeemable convertible preferred stock and stockholders’ equity
      		                                         229,457,000  
        liabilities, redeemable convertible preferred stock and stockholders’ deficit
      		                                           
        stockholders’ deficit:
      		                                           
        accumulated other comprehensive gain
      		                                          38,000 
        total stockholders’ deficit
      		                                          -47,139,000 
        total liabilities, redeemable convertible preferred stock and stockholders’ deficit
      		                                          166,435,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 
                                                  
          cash flow from operating activities
        		                                          
          net loss
        		-27,937,000  -27,892,000 -33,382,000 -31,021,000          17,624,000 -19,087,000 -21,319,000   -30,120,000 -21,649,000   -8,681,000 -24,263,000 -12,574,000 -15,006,000 11,153,000 -27,170,000 -22,531,000 -20,289,000 -25,542,000 -19,926,000 -11,829,000 -23,346,000 -18,875,000 -16,648,000 -14,673,000 -8,997,000 -9,335,000 -7,188,000 -7,283,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                          
          stock-based compensation expense
        		2,488,000 3,521,000 3,460,000 4,133,000 3,673,000 3,737,000 3,433,000 4,042,000 3,573,000 3,045,000 2,878,000 2,672,000 2,558,000 2,346,000 2,189,000 2,490,000 2,319,000 1,654,000 2,078,000 3,991,000 3,601,000 3,502,000 3,532,000 3,860,000 4,040,000 3,520,000 3,349,000 5,253,000 3,518,000 2,638,000 2,636,000 8,114,000 2,322,000 2,293,000 3,241,000 1,539,000 2,165,000 1,782,000 1,789,000 1,317,000 1,422,000 1,966,000 
          depreciation
        		932,000 1,049,000 932,000 1,065,000 1,014,000 1,011,000 1,132,000 1,392,000 1,196,000 1,335,000 945,000 1,086,000 1,075,000 834,000 1,341,000 1,204,000 2,812,000 1,482,000 1,224,000 1,185,000 1,274,000 987,000 1,062,000 926,000 842,000 758,000 715,000 676,000 616,000 579,000 566,000 516,000 456,000 436,000 433,000 409,000 317,000 164,000 160,000 152,000 136,000 164,000 
          amortization of premiums and discounts on marketable securities
        		-365,000 -530,000 -654,000 -791,000 -998,000 -1,513,000 -2,061,000 -2,464,000 -1,931,000 -1,794,000 -1,807,000 -8,000 -17,000 7,000 -25,000 -19,000 21,000 25,000 111,000 111,000 102,000 84,000 65,000 66,000 -188,000 -657,000 -1,083,000 -1,290,000 -554,000 -600,000 -655,000 -599,000 -309,000 -221,000 28,000 77,000 92,000 125,000 144,000 196,000 231,000 191,000 
          loss on disposal of fixed assets
        		 62,000 0 49,000 30,000 32,000 192,000 227,000 59,000 35,000 19,000 80,000 44,000                              
          non-cash lease expense
        		1,269,000 1,262,000 1,233,000 1,155,000 1,221,000                                      
          changes in operating assets and liabilities:
        		                                          
          accounts receivable
        		267,000 1,425,000 -1,512,000 -51,000 -119,000 14,450,000 -14,252,000 -865,000 79,313,000    -25,000,000                              
          related party collaboration receivable
        		 700,000 0 -364,000 189,000 3,038,000 -2,165,000 1,071,000 721,000 -88,000 97,000 -3,022,000 -71,000 -32,000 -74,000 55,000 526,000 433,000 593,000 2,495,000 3,759,000 4,677,000 -3,000 3,597,000 2,213,000                  
          prepaid expenses and other current assets
        		471,000  3,153,000 -2,694,000 868,000  -1,117,000 -1,186,000 -794,000  344,000 -2,097,000 1,411,000  -1,658,000 191,000 -185,000  838,000 570,000 323,000  384,000 1,050,000 -55,000 1,623,000 -2,914,000 2,959,000 7,000 -3,810,000 1,257,000 -1,689,000 305,000 -134,000 799,000 7,000 958,000 -536,000 -384,000 222,000 -149,000 -477,000 
          accounts payable
        		-2,290,000 2,897,000 312,000 -830,000 -1,362,000 836,000 555,000 -4,974,000 5,975,000 -1,666,000 1,611,000 -2,039,000 1,132,000 1,229,000 119,000 18,000 626,000 -18,000 -198,000 -2,387,000 2,543,000 -2,752,000 1,341,000 -2,770,000 745,000 -390,000 1,796,000 -31,000 1,223,000 -684,000 -136,000 186,000 352,000 109,000 604,000 -523,000 280,000 -237,000 333,000 -1,243,000 1,085,000 71,000 
          accrued expenses
        		-5,126,000 -3,185,000 2,831,000 2,972,000 -5,118,000 2,729,000 1,169,000 2,755,000 -9,305,000 5,771,000 1,940,000 1,418,000 -122,000 -4,684,000 5,188,000 -158,000 -3,494,000 -423,000 445,000 400,000 -3,757,000 -3,040,000 1,128,000 58,000 -4,626,000 5,484,000 4,267,000 2,557,000 -580,000 1,706,000 605,000 -1,679,000 -2,232,000 950,000 3,219,000 1,235,000 -504,000 335,000 682,000 2,388,000 -769,000 836,000 
          operating lease liabilities
        		-1,933,000 -1,869,000 -1,836,000 -1,792,000 -1,730,000 -1,622,000 -1,594,000 -995,000 891,000 -731,000 -717,000 -702,000 -683,000 -642,000 -633,000 -1,340,000 -1,307,000 -1,080,000 -457,000 -1,023,000 -868,000 15,809,000 -806,000 -790,000 -774,000 -646,000 -634,000 -620,000 -606,000              
          deferred revenue
        		-1,195,000 -10,459,000 -11,075,000 -2,731,000 -4,542,000 -4,384,000 -5,207,000 -24,608,000 -10,643,000 -6,846,000 -962,000 -1,503,000 18,725,000 1,806,000 -30,862,000 -560,000 53,347,000 2,920,000 -549,000 -332,000 -3,760,000 -1,854,000 -121,096,000 -19,383,000 -8,343,000 -17,142,000 -8,092,000 -42,546,000 148,611,000 -2,008,000 -2,094,000 -2,575,000 68,057,000 -6,345,000 -1,148,000 -1,178,000 -1,464,000 -2,363,000 -3,669,000 -4,201,000 -4,349,000 -2,622,000 
          net cash from operating activities
        		-33,419,000 -30,263,000 -31,048,000 -33,261,000 -37,895,000 -14,529,000 -27,968,000 -31,580,000 58,767,000 -23,760,000 -21,051,000 -835,000 123,565,000 -12,244,000 -16,206,000 -18,485,000 34,426,000 11,195,000 -20,709,000 -22,717,000 -21,294,000 -21,977,000 -24,740,000 -21,201,000 -28,798,000 -23,360,000 -21,579,000 -31,557,000 125,162,000 -24,348,000 -17,647,000 -22,502,000 48,610,000 -14,834,000 -15,887,000 -16,335,000 -14,294,000 -13,092,000 -10,189,000 -9,714,000 -9,487,000 -9,557,000 
          capital expenditures
        		-14,000 -626,000 -207,000 -1,105,000 -658,000 -155,000 -258,000 -967,000 -2,141,000 -755,000 -782,000 -1,210,000 -509,000 -933,000 -278,000 -1,242,000 -38,000 -347,000 -660,000 -227,000 -375,000 -3,556,000 -5,152,000 -1,882,000 -1,507,000 -3,376,000 -1,174,000 -2,064,000 -1,104,000 -523,000 -849,000 -1,326,000 -1,607,000 -161,000 -412,000 -467,000 -2,945,000 -3,869,000 -503,000 -197,000 -460,000 -121,000 
          free cash flows
        		-33,433,000 -30,889,000 -31,255,000 -34,366,000 -38,553,000 -14,684,000 -28,226,000 -32,547,000 56,626,000 -24,515,000 -21,833,000 -2,045,000 123,056,000 -13,177,000 -16,484,000 -19,727,000 34,388,000 10,848,000 -21,369,000 -22,944,000 -21,669,000 -25,533,000 -29,892,000 -23,083,000 -30,305,000 -26,736,000 -22,753,000 -33,621,000 124,058,000 -24,871,000 -18,496,000 -23,828,000 47,003,000 -14,995,000 -16,299,000 -16,802,000 -17,239,000 -16,961,000 -10,692,000 -9,911,000 -9,947,000 -9,678,000 
          cash flow from investing activities
        		                                          
          purchases of property and equipment
        		-14,000 -626,000 -207,000 -1,105,000 -658,000 -155,000 -258,000 -967,000 -2,141,000 -755,000 -782,000 -1,210,000 -509,000 -933,000 -278,000 -1,242,000 -38,000 -347,000 -660,000 -227,000 -375,000 -3,556,000 -5,152,000 -1,882,000 -1,507,000 -3,376,000 -1,174,000 -2,064,000 -1,104,000 -523,000 -849,000 -1,326,000 -1,607,000 -161,000 -412,000 -467,000 -2,945,000 -3,869,000 -503,000 -197,000 -460,000 -121,000 
          purchases of marketable securities
        		-43,441,000 -12,503,000 -6,636,000 -37,866,000 -76,924,000 -131,018,000 -40,808,000 -90,007,000 -203,852,000 -28,993,000 -166,522,000   0 0 -34,888,000 -19,960,000     -45,424,000 -9,992,000   -85,163,000 -94,716,000 -99,373,000 -214,979,000 -58,847,000 -69,344,000 -195,046,000 -9,991,000         -120,116,000 
          proceeds from sales and maturities of marketable securities
        		51,556,000 60,553,000 41,731,000 40,904,000 118,783,000 103,970,000 105,418,000 55,031,000 109,928,000 56,581,000 9,000,000 5,000,000 15,000,000 15,000,000    10,000,000 15,000,000                        
          net cash from investing activities
        		8,101,000 47,424,000 34,888,000 1,933,000 41,201,000 -27,203,000 64,352,000 -35,943,000 -96,065,000 26,833,000 -158,304,000 -24,663,000 14,491,000 14,067,000 34,722,000 -36,130,000 -19,998,000 -5,464,000 14,340,000 22,405,000 34,625,000 -21,516,000 27,356,000 -1,838,000 108,993,000 26,462,000 22,610,000 -2,888,000 -136,661,000 28,630,000 -1,193,000 -59,372,000 58,402,000 -60,101,000 -2,768,000 38,533,000 20,655,000 -14,142,000 6,611,000   -99,577,000 
          cash flow from financing activities
        		                                          
          proceeds from the exercise of stock options
        		294,000 21,000 85,000 79,000 82,000 127,000 93,000 90,000 78,000 23,000 415,000 1,229,000 185,000 27,000 15,000 575,000 12,000 0 0 0 28,000 124,000 510,000 1,651,000 34,000 108,000 1,608,000 714,000 284,000 417,000 944,000 1,117,000 1,411,000 -293,000 556,000 498,000 602,000   89,000 4,000  
          proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs
        		3,038,000                                          
          net cash from financing activities
        		3,332,000 136,000 85,000 513,000 82,000 574,000 14,000 571,000 112,856,000 460,000 331,000 1,548,000 31,306,000 276,000 15,000 807,000 12,000 227,000 0 357,000 28,000 486,000 510,000 2,133,000 34,000 300,000 1,724,000 1,069,000 77,901,000 435,000 1,368,000 1,117,000 1,829,000 58,264,000 556,000 498,000 602,000 368,000 53,000 89,000 4,000 73,910,000 
          net increase in cash, cash equivalents, and restricted cash
        		-21,986,000 17,297,000 3,925,000 -30,815,000 3,388,000 -41,158,000 36,398,000 -66,952,000 75,558,000   -23,950,000 169,362,000  18,531,000 -53,808,000 14,440,000  -6,369,000 45,000 13,359,000  3,126,000 -20,906,000 80,229,000  2,755,000 -33,376,000 66,402,000  -17,472,000 -80,757,000 108,841,000          
          cash, cash equivalents, and restricted cash, beginning of period
        		68,036,000  0 0 74,241,000  0 0 70,395,000  0 0 100,474,000    119,212,000    106,219,000    86,777,000    47,594,000              
          cash, cash equivalents, and restricted cash, end of period
        		46,050,000  3,925,000 -30,815,000 77,629,000  36,398,000 -66,952,000 145,953,000  -179,024,000 -23,950,000 269,836,000    133,652,000    119,578,000    167,006,000    113,996,000              
          net income
        		     -34,487,000 -9,044,000 -10,141,000 -11,330,000 56,395,000 -25,901,000 -22,208,000 124,044,000     5,709,000    -15,926,000                     
          adjustments to reconcile net income to net cash from operating activities:
        		                                          
          impairment charge on leased facility
        		     0 0                                    
          prepaid expenses and other assets
        		                                          
          proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering
        		                                          
          proceeds from the issuance of common stock in connection with the 2023 novartis stock purchase agreement
        		     0 0 0 19,305,000                                  
          proceeds from the issuance of common stock in connection with the 2023 neurocrine collaboration agreement
        		         0 0 0 31,121,000                              
          proceeds from the purchase of common stock under espp
        		 115,000 0   447,000 -79,000   437,000 -84,000   249,000 0   227,000 0   362,000 0   192,000 116,000   18,000 424,000 0 418,000          
          cash, cash equivalents, and restricted cash beginning of period
        		             0 0   0 0   0 0   0 0   0 0 0 32,265,000          
          cash, cash equivalents, and restricted cash end of period
        		             2,099,000 18,531,000   5,958,000 -6,369,000   -43,007,000 3,126,000   3,402,000 2,755,000   4,717,000 -17,472,000 -80,757,000 141,106,000          
          supplemental disclosure of cash and non-cash activities
        		                                          
          operating lease right-of-use asset obtained in exchange for operating lease liability
        		     0 0 0 26,751,000                                  
          capital expenditures incurred but not yet paid
        		           -57,000 109,000 -26,000 -73,000 -115,000 228,000 58,000 -89,000 94,000 17,000 377,000 -1,149,000 1,538,000 65,000 77,000 340,000 8,000 9,000    25,000   -292,000 387,000      
          proceeds from the issuance of common stock and pre-funded warrants in connection with the 2023 novartis stock purchase agreement
        		                                          
          other non-current assets
        		        -15,000         0 0   68,000 68,000   70,000 261,000   0 0 0 -180,000    -1,490,000 -50,000 0 0 57,000 0 
          gain on lease termination
        		                                          
          operating lease, right-of-use assets
        		                                          
          proceeds from the issuance of common stock in connection with the underwritten public offering
        		     0 0 0 93,473,000                                  
          operating lease, right-of-use asset
        		      991,000 1,375,000 1,057,000  502,000 488,000 469,000  449,000 1,476,000 1,080,000  343,000 971,000 951,000  857,000 750,000 734,000 859,000 710,000 712,000 670,000              
          change in fair value of common stock and warrants to purchase equity securities
        		                                          
          net increase in cash and cash equivalents
        		                                 -16,671,000 -18,099,000 22,696,000 6,963,000 -26,866,000 -3,525,000 33,137,000 2,586,000 -35,224,000 
          operating lease right-of-use assets obtained in exchange for operating lease liabilities
        		                                          
          other non-cash items
        		              1,000    0 1,422,000 -3,882,000  -830,000 46,000 808,000 198,000 -978,000 133,000 -965,000 362,000 142,000 766,000 -411,000 -93,000 283,000 -999,000 855,000 1,118,000     
          other non-current liabilities
        		              136,000                   0 0 0 1,000,000     -3,000 
          net decrease in cash, cash equivalents, and restricted cash
        		                                          
          proceeds from maturities of marketable securities
        		                    35,000,000  42,500,000 15,000,000 110,500,000  118,500,000 98,500,000 79,300,000  69,000,000 137,000,000 70,000,000  47,500,000 39,000,000 23,600,000  61,700,000 55,000,000 13,000,000  
          in-kind research and development expenses
        		                         0 0 224,000 392,000 0 0 0 176,000 0 0 69,000 44,000 193,000 237,000    
          proceeds from sale of equipment
        		                         1,000 0                
          proceeds from the issuance of common stock in connection with the neurocrine collaboration agreement
        		                         0 0 0 77,617,000              
          lease incentive benefit
        		                             0    0 0 414,000 101,000      
          loss from sale of equipment
        		                            122,000              
          noncurrent assets
        		                    69,000    69,000                  
          deferred rent
        		                                       38,000 37,000 -72,000 
          change in fair value for common stock and warrants to purchase equity securities
        		                                          
          proceeds from maturities or sales of marketable securities
        		                                          
          impact of adopting new accounting standards
        		                             0 0 0 20,050,000          
          proceeds from the issuance of common stock net of discount and issuance costs
        		                                          
          collaboration receivable
        		                          -3,491,000                
          unbilled receivable
        		                          -479,000                
          proceeds from the issuance of stock net of discount and issuance costs
        		                                          
          change in fair value of preferred stock tranche liability
        		                                         0 
          change in restricted cash
        		                                     50,000 0 0 -471,000  
          cash and cash equivalents, beginning of period
        		                                 0 0 0 36,641,000 0 0 0 31,309,000 0 
          cash and cash equivalents, end of period
        		                                 -16,671,000 -18,099,000 22,696,000 43,604,000 -26,866,000 -3,525,000 33,137,000 33,895,000 -35,224,000 
          accretion of redeemable convertible preferred stock to redemption value
        		                                         1,328,000 
          conversion of redeemable convertible preferred stock to common stock
        		                                          
          purchases of marketable securities and warrants
        		                                          
          non-cash interest on convertible promissory notes payable
        		                                          
          expense related to shares issued in connection with services performed
        		                                          
          proceeds from the issuance of redeemable convertible preferred stock net of discount and issuance costs
        		                                          
          proceeds from the exercise of common stock and restricted stock
        		                                          
          exchange of promissory notes payable and accrued interest into series a redeemable convertible preferred stock and tranche rights
        		                                          
          deferred initial public offering costs
        		                                          
          proceeds from the exercise of stock options and issuance of restricted stock
        		                                          
          deferred initial public offering costs included in accrued expenses
        		                                          
          proceeds from the issuance of common stock and restricted stock
        		                                         72,946,000 
          net cash from (used) in investing activities
        		                                        12,069,000  
          proceeds from issuance of preferred stock
        		                                          
          proceeds from issuance of series a preferred stock
        		                                          
          proceeds from issuance of series b preferred stock
        		                                          
          proceeds from the issuance of series a redeemable convertible preferred stock and tranche rights, net of issuance costs
        		                                          
          proceeds from the issuance of series b redeemable convertible preferred stock net of discount and issuance costs